Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
LENZ Therapeutics ( (LENZ) ) has shared an announcement.
On July 31, 2025, LENZ Therapeutics announced the FDA approval of VIZZ, an aceclidine-based eye drop for treating presbyopia in adults, marking a significant milestone as the first of its kind in the United States. The approval is based on successful Phase 3 trials demonstrating VIZZ’s efficacy in improving near vision for up to 10 hours, with product availability expected by mid-Q4 2025. This development is anticipated to transform treatment options for presbyopia, potentially becoming the standard of care for the 128 million affected adults in the U.S., and reflects the company’s commitment to addressing age-related vision loss.
The most recent analyst rating on (LENZ) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on LENZ Therapeutics stock, see the LENZ Stock Forecast page.
Spark’s Take on LENZ Stock
According to Spark, TipRanks’ AI Analyst, LENZ is a Neutral.
LENZ Therapeutics is navigating significant financial challenges with ongoing losses and negative cash flows, underscoring the need for strategic improvement to achieve profitability. While the earnings call highlights positive regulatory and commercial developments, the stock is burdened by a weak valuation profile due to negative earnings. The technical analysis presents a neutral to slightly bearish outlook, which, combined with financial hurdles, results in a cautious overall score.
To see Spark’s full report on LENZ stock, click here.
More about LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. The company is headquartered in San Diego, California, and is working on establishing licensing partnerships internationally to provide access to VIZZ globally.
Average Trading Volume: 272,855
Technical Sentiment Signal: Buy
Current Market Cap: $891.4M
For a thorough assessment of LENZ stock, go to TipRanks’ Stock Analysis page.